DNA-crosslinker cisplatin eradicates bacterial persister cells

Nityananda Chowdhury, Thammajun L. Wood, Mariano Martínez-Vázquez, Rodolfo García-Contreras, Thomas K. Wood

Research output: Contribution to journalArticlepeer-review

54 Scopus citations

Abstract

For all bacteria, nearly every antimicrobial fails since a subpopulation of the bacteria enter a dormant state known as persistence, in which the antimicrobials are rendered ineffective due to the lack of metabolism. This tolerance to antibiotics makes microbial infections the leading cause of death worldwide and makes treating chronic infections, including those of wounds problematic. Here, we show that the FDA-approved anti-cancer drug cisplatin [cis-diamminodichloroplatinum(II)], which mainly forms intra-strand DNA crosslinks, eradicates Escherichia coli K-12 persister cells through a growth-independent mechanism. Additionally, cisplatin is more effective at killing Pseudomonas aeruginosa persister cells than mitomycin C, which forms inter-strand DNA crosslinks, and cisplatin eradicates the persister cells of several pathogens including enterohemorrhagic E. coli, Staphylococcus aureus, and P. aeruginosa. Cisplatin was also highly effective against clinical isolates of S. aureus and P. aeruginosa. Therefore, cisplatin has broad spectrum activity against persister cells. Biotechnol. Bioeng. 2016;113: 1984–1992.

Original languageEnglish (US)
Pages (from-to)1984-1992
Number of pages9
JournalBiotechnology and bioengineering
Volume113
Issue number9
DOIs
StatePublished - Sep 1 2016

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Bioengineering
  • Applied Microbiology and Biotechnology

Fingerprint Dive into the research topics of 'DNA-crosslinker cisplatin eradicates bacterial persister cells'. Together they form a unique fingerprint.

Cite this